Mahamaya Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/12/2025 ,inter alia, to consider and approve the Unaudited Standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mahamaya Lifesciences has informed BSE that its Board of Directors will meet on December 2, 2025 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2025, along with the Limited Review Report. The trading window for the company's shares remains closed and will stay shut until 48 hours after the results are declared. This is a routine regulatory intimation under SEBI Listing Regulations and does not contain any actual financial figures.
No direct impact on the stock or shareholders at this stage. Investors should watch for the actual H1 FY26 results on December 2, which could move the stock depending on performance vs. expectations.